Article Text
Statistics from Altmetric.com
STUDY DESIGN
Design:
randomised placebo-controlled trial (DART-AD). ISRCTN33368770.
Allocation:
concealed.*
Blinding:
blinded {patients, caregivers and relatives, clinicians, people administering trial drugs, and outcome assessors}†.*
STUDY QUESTION
Setting:
nursing or residential care facilities in the UK.
Patients:
165 patients (mean age 85 y, 76% women) who lived in nursing or residential homes, had possible or probable Alzheimer disease (AD, National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association criteria) and a Mini-Mental State Examination score >6 or Severe Impairment Battery score >30, and were taking antipsychotic drugs (APDs) for ⩾3 months for behavioural or psychiatric disturbance (risperidone, ⩾0.5 mg/d or ⩾10 mg of chlorpromazine or equivalent of thioridazine, haloperidol, or trifluoperazine). Exclusion criteria were inability to take capsules or complete baseline …
Footnotes
Source of funding: UK Alzheimer's Research Trust.